十一月 2025
- Home
- Akouos
十一月 2025的Akouos市场份额分析
Our Mission: Healthy Hearing Available to All.
We are a precision genetic medicine company focused on developing gene therapies with the potential to restore, improve and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss.
Akouos(包含公司地区分支机构)
查看更多网站流量和参与度信息- akouos.com
Akouos收入截至 十一月 2025为 25M - 50M
Akouos主要域名产生的收入
3 年中Akouos主要域名的收入
Akouos主要域名的收入
Akouos热门域名的总访问量
了解Akouos市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Akouos热门域名的平均访问时长
分析Akouos参与度指标。
过去 3 个月的平均访问时长
子公司明细
Akouos热门域名的平均页面浏览量
了解Akouos如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Akouos 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Akouos, Inc. had issues with possible breaches of fiduciary duty and other violations of law on Oct 18th '22.Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akouos, Inc. ("Akouos" or the "Company") (NASDAQ: AKUS ), in connection with the proposed tender offer for the Company by Eli Lilly and Company (NYSE: LLY ).
十月 21, 2022阅读更多
新闻Lillyindia acquires Akouos, Inc. for $487M.Eli Lilly and Co will acquire genetic medicine developer Akouos Inc for about $487 million in cash as the drugmaker aims to bolster its arsenal of gene therapies that target a range of disabilities.
十月 18, 2022阅读更多
新闻Akouos, Inc. hired Aaron Tward as chief scientific officer on Mar 1st '22.Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Aaron Tward, M.D., Ph.D., as chief scientific officer.
三月 10, 2022阅读更多
查看 Akouos 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。